“The PCD is listed on clinicaltrials.gov for the end of 2025, so expect beginning 2026 potential data.”

In context

“tial to expand in pretty much all our key markets outside of the US too. Because of our profile is differentiated and will support our standard of care status, we believe in our key market. And three, which is often underestimated, we, after three years of hard work, have finally reached access, reimbursement in 46 markets. We just received actually reimbursement in Korea in March of 2025. So that will kind of flow into our business and welcome you to sustain significant growth with the year. Thank you, Alexandre. Chris Gipur. Chris Boshoff: And oral small molecule Gipa antagonist was discovered in-house. It's potentially first in class oral small molecule GIP antagonist. And the phase two study is now ongoing. This is a study in obesity and combination with laraglutide, with the GLP one. The PCD is listed on clinicaltrials.gov for the end of 2025, so expect beginning 2026 potential data. If the data are positive in the phase two study, then could be a potential to be using combinations to drive weight loss both with internal or ex opportunities. Albert Bourla: Thank you very much, Chris. And then Andrew. Disconnect between our projections that you came to interrogate very carefully and your colleagues in your previous life. Andrew Baum: Alright. Well, thank you for the opportunity, Albert. So I'd start with the two ADCs, which are now in phase three first-line trials for a non-small cell and hepNex, so SV and PDL1V. Now part of the reason I think that Street may have these may have flown under the radar is they move very, very quickly on the back of very strong phase one data straight into phase three. And so I think some focus on that will be useful. We obviously have th”